Skip to main content

Clinical Trials Using Nivolumab

Review the clinical trials studying nivolumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 187

Studying the Side Effects of Different Dosing Strategies of Nivolumab and Pembrolizumab for the Treatment of Solid Tumors
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Nivolumab for the Treatment of DNA Repair-Mutated, Biochemically Recurrent Prostate Cancer, The NivoCure Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Nivolumab Alone or in Combination with Relatlimab or Ipilimumab for the Treatment of Resectable Stage III-IVA Head and Neck Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Nivolumab with or without Ipilimumab or Relatlimab in Treating Patients with Unresectable, Metastatic, or Refractory Basal Cell Carcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
High-Dose Interleukin-2, Ipilimumab and Nivolumab for the Treatment of Patients with Stage III-IV Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Studying Patient Preference for Subcutaneous or Intravenous Administration of Nivolumab and Pembrolizumab for the Treatment of Locally Advanced or Advanced/Metastatic Solid Tumors, PSI-Immune Trial
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Adjuvant Sacituzumab Govitecan and Nivolumab for the Treatment of Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Nivolumab plus Axitinib for the Treatment of Stage III or IV Melanoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Time-of-Day Specified Ipilimumab and Nivolumab for the Treatment of Stage IV Unresectable Melanoma, The TIME Trial
Status: Active
Location: 2 locations
Immunotherapy and Cryoablation of an Enlarging Tumor for the Treatment of Unresectable Metastatic Melanoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Neoadjuvant Anti-PD-L1 Immunotherapy for the Treatment of Advanced Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
STING Agonist (IMSA101) and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy with Nivolumab for the Treatment of Stage IV Renal Cell Carcinoma in Patients who Progressed on Immunotherapy, SPARK Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Immunotherapy versus Chemoimmunotherapy Guided by Circulating Tumor DNA-Based Molecular Response for the Treatment of Stage IV Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Combined Immunotherapy with Ipilimumab and Nivolumab or Nivolumab and Relatlimab and Radiation Therapy before Surgery for the Treatment of Sinonasal and Anorectal Melanoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neoadjuvant Zanzalintinib Plus Nivolumab for the Treatment of Locally Advanced and/or Inoperable Clear Cell Renal Cell Cancer, EXPLORE-RCC Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Nivolumab, Ipilimumab, and Cabozantinib for the Treatment of Untreated Renal Cell Carcinoma with Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Intralesional Nivolumab for the Treatment of Patients with High-Risk Oral Pre-malignant Lesions
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ipilimumab and Nivolumab before Surgery for the Treatment of Recurrent, High Risk, Resectable Stage IIIB-IV Metastatic Melanoma (NeoRelapse)
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Nivolumab with or without Relatlimab given Prior to Surgery and Temozolomide and Radiation Therapy for the Treatment of IDH Wildtype Newly Diagnosed Glioblastoma
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
NC410 in Combination with Nivolumab and FOLFIRINOX Chemotherapy, with or without Ipilimumab, for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Circulating Tumor DNA Monitoring for Treatment Response Prediction and Treatment Reduction after Surgery in Patients with Stage IB, II, and IIIB Non-small Cell Lung Cancer, DNA-PREDICT Trial
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Neoadjuvant Opdualag versus Nivolumab for the Treatment of Resectable High-Risk Basal Cell Carcinoma
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California